These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23667506)

  • 21. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
    Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
    J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
    Vieyres G; Dubuisson J; Patel AH
    J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.
    Dhillon S; Witteveldt J; Gatherer D; Owsianka AM; Zeisel MB; Zahid MN; Rychłowska M; Foung SK; Baumert TF; Angus AG; Patel AH
    J Virol; 2010 Jun; 84(11):5494-507. PubMed ID: 20237087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
    Prentoe J; Jensen TB; Meuleman P; Serre SB; Scheel TK; Leroux-Roels G; Gottwein JM; Bukh J
    J Virol; 2011 Mar; 85(5):2224-34. PubMed ID: 21123377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
    Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
    PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.
    Li YP; Ramirez S; Mikkelsen L; Bukh J
    J Virol; 2015 Jan; 89(1):811-23. PubMed ID: 25355880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
    Akram M; Idrees M; Hussain A; Afzal S; Ilyas M; Zafar S; Aftab M; Badar S; Khubaib B
    Virol J; 2011 May; 8():253. PubMed ID: 21605410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
    Pellicelli AM; Romano M; Stroffolini T; Mazzoni E; Mecenate F; Monarca R; Picardi A; Bonaventura ME; Mastropietro C; Vignally P; Andreoli A; Marignani M; D'Ambrosio C; Miglioresi L; Nosotti L; Mitidieri O; Gentilucci UV; Puoti C; Barbaro G; Barlattani A; Furlan C; Barbarini G;
    BMC Gastroenterol; 2012 Nov; 12():162. PubMed ID: 23157720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
    Hui CK; Yuen MF; Sablon E; Chan AO; Wong BC; Lai CL
    J Infect Dis; 2003 Apr; 187(7):1071-4. PubMed ID: 12660921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.